Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies

(2:37)

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

(45)

Fully human anti-CD19 and CD22 bispecific tandem CAR-T

(2:12)

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma

(1:36)

Bispecific anti-CD20, anti-CD19 CAR-Ts for R/R NHL

(2:)

Bispecific CD19/22 CAR therapy in children and young adults with ALL

(5:5)

Selecting between anti-CD20 bispecific antibodies and anti-CD19 CAR T-cells in third-line NHL

(3:26)

Bispecific antibodies for R/R aggressive B-cell lymphomas

(1:30)

First-in-human study of TG-1801, a CD19/CD47 bispecific antibody ± ublituximab in BCL

(1:22)

CIPO2015: Dual Targeting of CD19 \u0026 CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Receptor

(11:22)

First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL

(58)

Understanding Bispecific Antibodies

(3:41)

Treating Lymphoma with Bispecific Antibodies | LRF Webinars

(1:8:32)

Bispecific antibodies in B-ALL; blinatumomab

(3:44)

Bispecific Antibodies in Lymphoma

(26:27)

CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma

(2:22)

Understanding Bispecific Antibodies

(4:32)

Chimeric Antigen Receptor (CAR) Therapy

(10:27)

TNB-486: interim results of a CD19/CD3 T-cell engager in R/R follicular lymphoma

(6:24)

Antibody-based and bispecific T-cell dependent therapies

(4:34)